$GLSI News

Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027

Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom

HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69

Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01

Greenwich LifeSciences Expects Q2 Cash Burn To Be ~$2M, Down From $4.7M In Q1, With Cash Balance Of ~$8.9M As Of June And Expected Burn Rate Of $2-4M Per Quarter Going Forward

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In Europe

Greenwich LifeSciences The Overlooked Need

Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Q4 EPS $(0.58) Misses $(0.31) Estimate

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Published Abstract And Poster On Its Phase III FLAMINGO-01 Trial For GLSI-100 To Prevent Breast Cancer Recurrences From The ASCO Annual Meeting 2026

Greenwich LifeSciences Reports Progress in Late-Stage Breast Cancer Immunotherapy Trial

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Greenwich LifeSciences Receives Nasdaq Noncompliance Notice

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026